| US 7,494,658 B2 | ||
| Papilloma virus truncated L1 protein and fusion protein constructs | ||
| Michael Hallek, Munich (Germany); and Alexander Burger, Munich (Germany) | ||
| Assigned to Medigene AG, Muenchen-Martinsried (Germany) | ||
| Filed on Jul. 13, 2005, as Appl. No. 11/179,478. | ||
| Application 11/179478 is a division of application No. 10/654129, filed on Sep. 04, 2003, granted, now 7,182,947. | ||
| Application 10/654129 is a division of application No. 09/824017, filed on Apr. 03, 2001, granted, now 6,649,167. | ||
| Application 09/824017 is a continuation of application No. 09/026896, filed on Feb. 20, 1998, abandoned. | ||
| Prior Publication US 2005/0249745 A1, Nov. 10, 2005 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. A61K 39/12 (2006.01) | ||
| U.S. Cl. 424—204.1 [435/69.1] | 10 Claims |
| 1. A fusion protein comprising:
(a) an amino acid sequence from a truncated first human papilloma-virus (HPV) L1 protein lacking one or more amino acids from
its carboxy terminus; and
(b) an amino acid sequence from a second HPV protein selected from the group consisting of E1, E2, E3, E4, E5, E6, and E7, wherein said fusion protein
(i) comprises only amino acids present in wild-type HPV proteins,
(ii) is capable of virus-like particle formation, and
(iii) is specifically immunogenic against HPV.
|